TG Therapeutics outlines $825M-$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Source: SeekingAlpha
2026-02-26 12:28:43 ET
More on TG Therapeutics
- TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
- TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade)
- 44th Annual J.P. Morgan Healthcare Conference
- TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M
- TG Therapeutics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
TG Therapeutics Inc.
NASDAQ: TGTX
TGTX Trading
-1.97% G/L:
$28.435 Last:
474,376 Volume:
$29.08 Open:
TGTX Latest News
March 09, 2026 07:30:00 am
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
TGTX Stock Data
$4,661,971,279
141,867,445
0.11%
146
N/A
Biotechnology & Life Sciences
Healthcare
US
Morrisville
